Post-translational modifications of tau protein in Alzheimer's disease
- PMID: 15517432
- DOI: 10.1007/s00702-004-0221-0
Post-translational modifications of tau protein in Alzheimer's disease
Abstract
Microtubule-associated protein tau undergoes several post-translational modifications and aggregates into paired helical filaments (PHFs) in Alzheimer's disease (AD) and other tauopathies. These modifications of tau include hyperphosphorylation, glycosylation, ubiquitination, glycation, polyamination, nitration, and proteolysis. Hyperphosphorylation and glycosylation are crucial to the molecular pathogenesis of neurofibrillary degeneration of AD. The others appear to represent failed mechanisms for neurons to remove damaged, misfolded, and aggregated proteins. This review summarizes the abnormal post-translational modifications of tau and discusses the pathophysiological relevance of hyperphosphorylation and glycosylation of tau. Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
Similar articles
-
Post-translational modifications of tau protein: implications for Alzheimer's disease.Neurochem Int. 2011 Mar;58(4):458-71. doi: 10.1016/j.neuint.2010.12.023. Epub 2011 Jan 6. Neurochem Int. 2011. PMID: 21215781 Review.
-
Post-translational modifications of tau protein.Bratisl Lek Listy. 2006;107(9-10):346-53. Bratisl Lek Listy. 2006. PMID: 17262986 Review.
-
Tau Abnormalities and the Potential Therapy in Alzheimer's Disease.J Alzheimers Dis. 2019;67(1):13-33. doi: 10.3233/JAD-180868. J Alzheimers Dis. 2019. PMID: 30507581 Review.
-
Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease.FEBS Lett. 2002 Feb 13;512(1-3):101-6. doi: 10.1016/s0014-5793(02)02228-7. FEBS Lett. 2002. PMID: 11852060
-
Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease.J Neurogenet. 2011 Dec;25(4):127-33. doi: 10.3109/01677063.2011.626471. J Neurogenet. 2011. PMID: 22091726 Review.
Cited by
-
Methylation as a key regulator of Tau aggregation and neuronal health in Alzheimer's disease.Cell Commun Signal. 2021 May 7;19(1):51. doi: 10.1186/s12964-021-00732-z. Cell Commun Signal. 2021. PMID: 33962636 Free PMC article. Review.
-
Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake.J Biol Chem. 2015 Aug 28;290(35):21652-62. doi: 10.1074/jbc.M115.657924. Epub 2015 Jun 30. J Biol Chem. 2015. PMID: 26126828 Free PMC article.
-
Comparative analysis of autophagy and tauopathy related markers in cerebral ischemia and Alzheimer's disease animal models.Front Aging Neurosci. 2015 May 19;7:84. doi: 10.3389/fnagi.2015.00084. eCollection 2015. Front Aging Neurosci. 2015. PMID: 26042033 Free PMC article.
-
The Role of Traditional Chinese Medicine Natural Products in β-Amyloid Deposition and Tau Protein Hyperphosphorylation in Alzheimer's Disease.Drug Des Devel Ther. 2023 Nov 13;17:3295-3323. doi: 10.2147/DDDT.S380612. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 38024535 Free PMC article. Review.
-
Hyperphosphorylation of Tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway.J Biol Chem. 2012 Oct 12;287(42):35222-35233. doi: 10.1074/jbc.M112.348300. Epub 2012 Aug 21. J Biol Chem. 2012. PMID: 22910909 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical